Osiris has successful pre-BLA meeting for stem cell therapy
This article was originally published in Scrip
Executive Summary
Osiris Therapeuticshas held a successful pre-BLA meeting with the US FDA for its stem cell therapy, Prochymal, for the treatment of graft-versus-host disease (GvHD) in which the content and timings of the BLA submission was finalised.
You may also be interested in...
P&G to co-promote Somaxon's Silenor in the US
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GSK's shingles vaccine begins Phase III studies
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
Optimer's fidaxomicin filing accepted in EU
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.